ASP Isotopes eyes $14M in PET Labs revenue as helium production nears
What's the deal? ASP IsotopesDealroom has a profile for this one. Try Dealroom → told shareholders yesterday that its subsidiary PET LabsDealroom has a profile for this one. Try Dealroom → is on track for roughly $14 million in 2026 revenue, up from about $6 million last year. The US company also confirmed helium production through its RenergenDealroom has a profile for this one. Try Dealroom → stake will start before September 30, 2026.
The numbers: PET Labs, which focuses on nuclear medicine applications, posted organic revenue growth of more than 50% in the first half of 2026 versus a year earlier. First batches of silicon-28 and ytterbium-176 — used in semiconductors and medical research — are set to ship in the second half of 2026.
What's the endgame? ASP Isotopes is diversifying beyond its core isotope business. Renergen's first helium phase targets roughly $27 million in annual revenue from helium and liquefied natural gas, with an Asian industrial gas firm already contracted for about 15% of output at over $600 per thousand cubic feet.
The company plans a separate listing for the helium unit via a reverse merger with ENDRADealroom has a profile for this one. Try Dealroom →. Afterwards, ASP Isotopes expects to hold about 89% of the new entity. A later, second production phase targets over $360 million in annual revenue at full capacity.
Why now? To fund these plans, ASP Isotopes recently completed a private placement of around $50 million. Investor QLE swapped roughly half its convertible notes into shares, leaving a balance of about $79.1 million. Management set a 2031 EBITDA target above $300 million.
What could go wrong? The targets stretch years out, and much hinges on execution. Shares closed Tuesday at €3.73, up 3.98% and about 21% above their 52-week low of €3.08, but the stock remains sharply down year-on-year.
The signal: ASP Isotopes is betting that nuclear medicine demand and helium supply — both structurally tight markets — can transform a small isotope maker into a diversified materials player by decade's end. The near-term revenue growth is real; the multibillion-dollar ambitions remain a promise.
Read more: ad-hoc-news.de
Image credit: Generated with Gemini
